Fusion antibody for presenting antigen-derived T cell epitope

USPTO issued Patent US12590156B2 on March 31, 2026, granting AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION exclusive rights to a fusion antibody technology for delivering CD8+ T cell antigen epitopes to cell cytoplasm. The patent covers a composition comprising the fusion antibody and methods for presenting antigen-derived epitopes on MHC-I molecules. The invention was filed as Application No. 17796788 on February 5, 2021, with 22 claims allowed.

This patent grant does not impose immediate compliance obligations on other entities. Companies developing T cell-based immunotherapies, vaccines, or related fusion antibody technologies should review the patent claims to assess potential licensing needs or freedom-to-operate concerns. The granted patent provides the assignee with enforceable exclusive rights in the US for the claimed fusion antibody compositions and methods.